Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pheochromocytoma × lanreotide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 4 Carcinoid Tumor 3 Pheochromocytoma 1 Paraganglioma 1 Neoplasm Metastasis 1 Gastrointestinal Neoplasms 1 Carcinoma, Merkel Cell 1

Interventions

lutetium Lu 177 dotatate 4 Temozolomide 4 Specimen Handling 3 3-Iodobenzylguanidine 3 olaparib 2 belzutifan 2 anlotinib 2 Magnetic Resonance Spectroscopy 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 tipifarnib 1 talazoparib 1 penpulimab 1 pazopanib 1 lenvatinib 1 lanreotide 1 guadecitabine 1 gallium Ga 68 dotatate 1 fostamatinib 1 copper dotatate CU-64 1 cabozantinib 1 atezolizumab 1 Ritonavir 1 Radiotherapy 1 Octreotide 1 Nivolumab 1 Melphalan 1 Lutetium-177 1 Lutetium 1 Ipilimumab 1 Indinavir 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03946527 2026-03-02

LAMPARA

Columbia University

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡